β lapachone (MedChemExpress)
Structured Review
β Lapachone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2-Lapachone/pm40103499-253-6-10
Average 94 stars, based on 11 article reviews
Images
Related Articles
Expressing:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Western Blot:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. MTT Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Colony Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Migration:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Wound Healing Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Transwell Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Tube Formation Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Binding Assay:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Transfection:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Control:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Knockdown:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. In Vivo:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Immunohistochemical staining:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Staining:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Droplet Countercurrent Chromatography:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. Purification:Article Title: Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer. Article Snippet: Mdivi-1 and Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone ( Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. |
